Publicacións en colaboración con investigadores/as de Eli Lilly and Company (1)

2019

  1. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 20, Núm. 12, pp. 1655-1669